Comments for AUXL - Stockpickr! Your Source for Stock Ideas

Comments for AUXL

Added By	Comments	Type	Date Added
kiwiloz	growth	Love	August 17, 2008
barrons2	COUNTING THE POTENTIAL for both Testim and Xiaflex, Lee and PAI partner Joon Yun see Auxilium shares reaching 100 over three years, up from about 37 recently. So far this year, the shares are up about 21%. Auxilium, founded in 1999, has yet to turn a profit. It lost more than $40 million in each of the past two years. But that could soon change. Lee values the Testim business at $1 billion. That assumes the business is worth about five times its expected sales three years from now -- a conservative valuation for a biotech concern. The Xiaflex business, he suggests, is worth about $3 billion. He figures the business can capture 20% of patients with the hand disorder by 2011, winning $300 million in sales. To that sum he applies a multiple of 10, which is not unusual for super-high-growth biotech businesses.	Love	August 09, 2008
Dan Jacobs	biotech spec that makes Xiaflex, in pahse 3 trials for Dupuytren's contractures, Peyronie's disease and frozen shoulder.	Love	January 14, 2008
Dan Jacobs	biotech spec that makes Xiaflex, in pahse 3 trials for Dupuytren's contractures, Peyronie's disease and frozen shoulder.	Love	January 14, 2008
High Dividends	11.6	Love	January 08, 2008
supratrade	BUY	Love	August 09, 2007
supratrade	BUY	Love	August 03, 2007
stockerblog	12.2 17.38%	Love	July 22, 2007
tshot98	long term payoff	Love	July 05, 2007
dcash	Very spectulative, but this is a $50,000,000 company soon to a $1.0B company.	Love	February 09, 2007